$339.93
+0.06 (+0.02%)
CSL News17 articles
ASX 200 Plunges 3.8% Amid Geopolitical Tensions and Rate Fears
Australian equities suffered a sharp 3.8% weekly decline, erasing approximately A$130 billion in market value. The sell-off was driven by escalating Middle East tensions and heightened expectations for RBA rate action.
Pro Medicus Rebounds 9% as Healthcare Tech Recovers from AI Selloff
Pro Medicus shares jumped over 9% on Friday, rebounding from a brutal selloff triggered by AI concerns. First-half revenue grew 28.4% to A$124.8 million, though it fell short of consensus expectations.
Pro Medicus Shares Surge 4.6% Amid Interim Revenue Growth
Pro Medicus shares gained 4.6% on Thursday, closing at A$121.49, despite remaining down 53% over the past year. Interim results showed strong revenue growth and a significant fair value gain from a 4D Medical investment.
CSL Shares Dip Amid Buyback Activity; Eli Lilly Partnership in Focus
CSL shares retreated 0.6% on Friday, ending a two-day advance. The company reported additional buyback activity and confirmed a new licensing agreement with Eli Lilly.
CSL Gains on Lilly Partnership, Buyback Activity Amid Leadership Shift
CSL Limited's stock advanced following a new drug development pact with Eli Lilly and ongoing share repurchases, while the board searches for a permanent CEO.
Wesfarmers Shares Slide Despite Profit Beat as Consumer Spending Concerns Mount
Wesfarmers shares tumbled over 5% despite reporting a half-year profit beat, as management flagged patchy consumer spending and upcoming price investments, overshadowing solid financial results.
CSL Shares Gain on $100M Lilly Kidney Drug Partnership, Buyback Continues
CSL Ltd shares advanced following a $100 million licensing agreement with Eli Lilly for the kidney disease drug clazakizumab. The company also continued its share repurchase program.
CSL Share Buyback Pace in Focus Amid Stock Slide and Leadership Transition
CSL Limited shares declined 0.4% to A$151.56, trailing the broader market, as the company reported additional share repurchases. Investors are monitoring the buyback program's progress ahead of an upcoming dividend payment.
Pfizer Shares Dip in Premarket Amid SEC Settlement, Partnership News
Pfizer stock edged lower in premarket trading following a $29 million SEC settlement agreement and a new biotech incubator partnership. Investors await key inflation data.
ASX 200 Ends Flat Amid AI Jitters; CSL Tumbles on CEO Exit
The S&P/ASX 200 closed virtually unchanged, dipping 2.7 points to 8,867.40. Insurance brokers slumped on AI competition fears, while CSL fell 5% after its CEO announced retirement.
CSL CEO Steps Down Ahead of Earnings, Shares Drop Nearly 5%
CSL announced CEO Paul McKenzie's retirement, with Gordon Naylor appointed interim leader. The biotech firm's shares fell 4.98% following the news.
CSL Leadership Transition Weighs on ASX Amid Tech Rebound
CSL shares fell nearly 5% following CEO Paul McKenzie's unexpected retirement, overshadowing a broader market recovery led by technology stocks. The S&P/ASX 200 closed essentially flat at 8,867.4.
CSL CEO Steps Down Ahead of Earnings, Interim Leader Named as Shares Slide
CSL announced CEO Paul McKenzie's retirement, with Gordon Naylor appointed interim chief effective February 11. The leadership change comes one day before the company's half-year results.
CSL Announces CEO Transition Ahead of Key Earnings Report
CSL shares gained 1.7% as CEO Paul McKenzie announced his retirement, with Gordon Naylor appointed interim chief. Investors await half-year results and a briefing on leadership succession.
ASX 200 Surges 1.85% on Tech and Real Estate Rally; Pepper Money Soars on Takeover Offer
Australian shares rebounded sharply Monday, with the S&P/ASX 200 climbing 1.85% to 8,870.1, led by technology and real estate sectors. Pepper Money surged over 30% after receiving a A$1.16 billion takeover bid.
CSL Shares Edge Lower Ahead of Key Half-Year Results and Dividend Announcement
CSL shares closed slightly lower as trading volume remained subdued, with investor focus shifting to the company's upcoming half-year financial results and interim dividend announcement scheduled for Wednesday.
CSL's Half-Year Results Approach Amid Market Volatility
CSL Ltd shares edged lower ahead of its half-year financial report and dividend announcement scheduled for February 11, as broader Australian markets experienced significant declines.